Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Up another tick! 0.001 x 0.003 now.
bidding .0009 up!!
100K-0.0009 x 50K-0.003 now.
135K-0.0008 x 50K-0.003 now.
Love go RGBOQ!!
0.0008 x 0.003 now. The next ask is 0.03! Super thin asks from L2!
Yes. The OS is only 9,778,940 shares and the MV is just $6845 at the
current price 0.0007!
THis just looks INCREDIBLE V!!
*** IS THAT RIGHT? IS THE MARKET CAP really that MEAGER at 6k??
*** What is the OS at? THANKS V!!!
** Curious to see how the BID and ask open up on this on MONDAY? This may just be one to follow maybe??? ~~ GREAT CALL V!!! ~~ I will put this one on RADAR!!! ~~ Any history fundamentals here V that investors should know about? Any fundamental story here that goes with this stock? Thanks V!!!
HAVE A GREAT WEEKEND, GREAT JOB V, I will watch this one carefully because of this LOW MARKET CAP in my opinion of speculations.... Just my own opinion of speculations do your own research and make up your own opinion of speculations.......
Thnx VI!, Trying bid .0007 on Monday!!
It is extremely undervalued and extremely oversold now! The current MV is just ridiculous $6K which means RGBOQ can surge up to 16666%!
Who sold 10K cheap shares at 0.0015? Why? Just $14K joke low MV now!
Wow, 50% down after 13900 shares slapped at the ask 0.003! Why sale?
0.0029 x 0.003 now. The next ask is 0.008!
0.0027 x 0.003 now. Only 40K shares left at 0.003...
27K+ shares bought at the ask so far! Only 40K shares left at 0.003!
0.0025 x 0.003 now.
It is up 20% so far! 0.002 x 0.003 now. Joke low MV $27K now! 1000%!
0.0025 x 0.003 now. The next ask is 0.008!
0.0018 x 0.0025 now.
It is up 150% so far! 0.0015 x 0.0025 now.
0.0014 x 0.0025 now.
0.0012 x 0.0025 now.
0.0011 x 0.0025 now.
Anyway 111K-0.0009 x 90K-0.0025 now.
The MM NITE manipulated the price down to the all time low 0.0004 by
selling just 1,350 shares, LOL!
Up 25% today! However the current MV is still joke low ($24K)...
The enterprise value is $7.89M or $0.8068 per share! And the current
MV is just $19K which is joke low. So it is easy to hit sub-dollar!
0.002 x 0.003 now. Super thin asks! Easy to hit multi pennies area!
0.0006 x 0.002 now.
The bid is up 25% so far! Huge bids at 0.0005 (1.44M shares or near
15% of OS)!
It is up 300% now! The MV is still joke low ($1.9K)! Easy 10-bagger!
If that happens this stock can easily surge to sub-dollars with only
9M shares OS and much lower float! Anyway based on the current SS it can easily explode to the current 52-week high 0.03 within one day!
Thanks.
Any chance coming out of BK.
That would be big catalyst.
Hopefully we can hear some news from the company or the court since it is such long the shareholders did not get any updating from RGBI!
The insiders ownership is 0.6% of OS! The stock was de-registered on
06/16/2011 and it became a clean reverse-merger shell! The number of shareholders was 269 on 03/27/2008. Totally 15 employees!
Here is the company website:
http://www.ivysportsmed.com/
Any news coming?
The cash value is $2.47M or $0.25 per share! The revenue is $1.5M or $0.22 per share! The gross profit is $681K!
The OS is 9,778,940 shares. So the MV at 0.005 is $4,889.47 or $4K!
New 52-week low 0.0005 was created today! The MV is now.
New ticker is RGBOQ, market cap is under 200,000, and being that the one who gave the financing for bk is a major shareholder one may reason that shares might stay. Low float POS "Q" nonetheless that might be worth a trade.
Regen Biologics files for bankruptcy
April 11, 2011 by MassDevice staff
Embattled ReGen Biologics Inc. files voluntary petitions for Chapter 11 bankruptcy protection and announces a $1 million private placement from one of its largest investors.
ReGen Biologics Inc. (PINK:RGBO) filed for Chapter 11 bankruptcy protection with the U.S. Bankruptcy Court for the District of Delaware.
The embattled maker of the Menaflex knee implant said in regulatory filings that the bankruptcy petition includes the company's wholly-owned subsidiary RBio Inc., but not its wholly-owned Swiss subsidiary, ReGen Biologics AG. The company will use cash flow from operations and proceeds from a loan it received from one of its largest institutional shareholders to pay the bills while it goes through the bankruptcy process.
ReGen said it raised $1 million through a private placement deal with the Sports Medicine Holding Company LLC, a division of Ivy Healthcare Capital II L.P., one of its largest shareholders. The private placement comes in the form of senior secured notes due August 31, which carry a 12 percent annual interest rate.
The bankruptcy filing adds yet another layer to the ReGen story, featuring a protracted and public battle with the FDA for nearly two years that has captured the attention of the medical device industry. Last week, the FDA rescinded its 2008 510(k) clearance of the Menaflex device, a bio-absorbable mesh implant designed to encourage the re-growth of damaged knee cartilage. The rescission means Hackensack, N.J.-based ReGen has to keep the device off the U.S. market until it can prove its safety and effectiveness to the FDA's satisfaction.
ReGen wasn't shy about voicing its displeasure over the rescission, with CEO Gerald Bisbee calling it "totally unbelievable."
The FDA said it wants ReGen to "discuss the appropriate marketing pathway for the device and what data it would need to provide a reasonable assurance of safety and effectiveness," five years after the company began the 510(k) application process.
ReGen has sunk $30 million into meeting requirements set by the FDA's Center for Devices & Radiological Health, according to Bisbee, "only to have the agency reverse decisions made by previous CDRH officials by stating that they were in error with no substantial evidence that is true."
The Menaflex 510(k) clearance in December 2008 came over the objections of FDA scientists who opposed clearing the device. In September 2009 the agency admitted that undue influence from four New Jersey congressmen and former commissioner Andrew von Eschenbach affected the decision to green-light the device and announced an investigation into the foofaraw.
In March, the agency's Orthopedic & Rehabilitation Devices Panel decided that, while the implant is reasonably safe, its effectiveness needed to be further analyzed. That decision came the same week that the FDA released a report saying ReGen failed to produce adequate evidence that device was safe before it was cleared to hit the market.
"It's unbelievable that after more than five years of 510(k) review of this product — and after being told by the ODE Director and the CDRH Director to file two separate 510(k) submissions for this device as a surgical mesh — [CDRH head Dr. Jeffrey] Shuren now says that they were wrong," Bisbee said in prepared remarks on March 22. "This arbitrary and unsubstantiated intention is an example of why the investment community is increasingly wary of investing in companies with products requiring FDA approval."
That wasn't the only shot Bisbee fired across the FDA's bow.
"We and they both know the agency has no legal authority to rescind its clearance of Menaflex. There is ample evidence the FDA completely botched its review of our Collagen Scaffold at every stage," he said. "After six years of unthinkable bias, mistakes and blunders, we are opting out of the FDA's administrative process and pursuing other legal options for continuing to market Menaflex to U.S. orthopedic surgeons and their patients."
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
174
|
Created
|
08/08/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |